Article
Excludes most of Asia: Tacrolimus licensing deal links Sucampo, Fujisawa
Bethesda, MD-Sucampo Pharmaceuticals Inc. has won the exclusive right to license Fujisawa's tacrolimus for ophthalmic use in the United States, Europe, and much of the world.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
